State Ledger
Company profile

Maze Therapeutics, Inc. CIK 1842295

Ticker
MAZE (Nasdaq)
Industry
Biological Products, (No Diagnostic Substances)
Headquarters
South San Francisco, CA 94080
Fiscal year end
2025 (FY)
Market Data
Close
$27.73
Change
+$0.62
Change %
2.29%
Volume
97,946

MAZE · trading date Oct 12, 2026 · previous close $27.11 · source: Alpaca (IEX feed, not consolidated full-market data).

Key Financials
Revenue
—
Net income
-$131.12M
Total assets
$397.13M
Total liabilities
$42.16M
Stockholders' equity
$354.97M
Cash & equivalents
$189.25M
Operating income
-$142.90M
Operating cash flow
-$111.94M
Capital expenditures
$794.0K

Fiscal year 2025, via 10-K filed 2026-03-25. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.

Financial Performance
Operating margin
—
Net margin
—
Free cash flow
-$112.73M
Free cash flow margin
—
Liabilities / assets
10.6%
Equity / assets
89.4%
CapEx / revenue
—
Operating cash flow / net income
0.85×

Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.

Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025 — -$131.12M $397.13M $42.16M $354.97M
2024 $167.50M $52.23M $240.54M $43.64M -$311.18M
Company Details
SIC code
2836
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form 4
2026-09-08
Financials filed via
Form 10-K
filed 2026-03-25

"Most recent SEC filing" may differ from the filing used for the financial figures above.

Location
South San Francisco, CA 94080
171 OYSTER POINT BOULEVARD, SUITE 300
Data & Methodology

SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:19 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.

← Back to California — Public Companies